Cargando…

Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies

BACKGROUND AND OBJECTIVE: The interleukin-36 signalling pathway is associated with pathogenesis of a number of inflammatory diseases. Spesolimab is a selective, humanised, IgG1 antibody that targets the interleukin-36 receptor. We aimed to evaluate the pharmacokinetics, safety and tolerability of si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joseph, David, Thoma, Christian, Haeufel, Thomas, Li, Xiujiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734218/ https://www.ncbi.nlm.nih.gov/pubmed/36451029 http://dx.doi.org/10.1007/s40262-022-01176-5

Ejemplares similares

Pharmacokinetics and pharmacodynamics of mepolizumab, an anti–interleukin 5 monoclonal antibody, in healthy Japanese male subjects
por: Tsukamoto, Naohiro, et al.
Publicado: (2015)

Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis
por: Shao, Shuai, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects
por: Umemura, Kazuo, et al.
Publicado: (2016)

Remission einer therapierefraktären generalisierten pustulösen Psoriasis unter dem Interleukin-36-Rezeptor-Inhibitor Spesolimab
por: Müller, Valentina Laura, et al.
Publicado: (2023)

Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study
por: Mrowietz, Ulrich, et al.
Publicado: (2021)

Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects
por: Oshima, Hiroyuki, et al.
Publicado: (2015)

Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects
por: Kong, Ronald, et al.
Publicado: (2019)

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
por: Fouqueray, Pascale, et al.
Publicado: (2022)

Spesolimab: First Approval
por: Blair, Hannah A.
Publicado: (2022)

Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
por: Burden, A. David, et al.
Publicado: (2023)

Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects
por: Cawello, Willi, et al.
Publicado: (2013)

Characterisation of a humanised bispecific monoclonal antibody for cancer therapy.
por: Bruynck, A., et al.
Publicado: (1993)

Comparative pharmacokinetics of maxacalcitol in healthy Taiwanese and Japanese subjects
por: Liu, Ming-Che, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
por: Li, Yinhua, et al.
Publicado: (2021)

Correction to: Spesolimab: First Approval
por: Blair, Hannah A.
Publicado: (2022)

Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
por: Yokote, Koutaro, et al.
Publicado: (2019)

Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
por: Sakurai, Yuuichi, et al.
Publicado: (2015)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects
por: Matsumoto, Yuki, et al.
Publicado: (2018)

Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants
por: Perera, Vidya, et al.
Publicado: (2022)

A Pharmacokinetic, Safety, and Tolerability Trial of Palovarotene in Healthy Japanese and Non-Japanese Participants
por: Dube, Louise, et al.
Publicado: (2023)

Spesolimab use in treatment of pyoderma gangrenosum
por: Guénin, Sophie H., et al.
Publicado: (2023)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects
por: Willen, Daniela, et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects
por: Shibata, Mai, et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Isavuconazonium Sulfate in Healthy Adult Japanese Subjects
por: Shirae, Shinichiro, et al.
Publicado: (2022)

In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
por: Blumenthal, R D, et al.
Publicado: (2008)

Pharmacokinetics and safety of cenobamate, a novel antiseizure medication, in healthy Japanese, and an ethnic comparison with healthy non‐Japanese
por: Yang, Eunsol, et al.
Publicado: (2021)

Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese
por: Choi, Yewon, et al.
Publicado: (2018)

Pharmacokinetic Profiles of Ticagrelor Orodispersible Tablets in Healthy Western and Japanese Subjects
por: Teng, Renli, et al.
Publicado: (2017)

1287. Pharmacokinetics, Safety, and Tolerability of Nacubactam after Single Coadministration with β-Lactams in Japanese Healthy Subjects
por: Asano, Masayo, et al.
Publicado: (2020)

Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects
por: Tsuda, Yasuhiro, et al.
Publicado: (2020)

A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults
por: Orito, Yuji, et al.
Publicado: (2022)

Reply: In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
por: Ashraf, S Q, et al.
Publicado: (2008)

Humanised monoclonal antibodies neutralise pertussis toxin by receptor blockade and reduced retrograde trafficking
por: Acquaye‐Seedah, Edith, et al.
Publicado: (2018)

Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer
por: Royer, B, et al.
Publicado: (2010)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
por: Frost, Charles, et al.
Publicado: (2018)

Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development
por: Kuester, K, et al.
Publicado: (2008)

Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects
por: Li, Yan, et al.
Publicado: (2018)

Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects
por: Tompson, Debra J., et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects
por: Scoble, Patrick J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a3fcs6o3g5kpbpccp64vanrnab